Danaher Life Sciences Unveils Mission Statement and Precision Medicine Solutions to Deepen Commitment to China Market

Shanghai, December 7, 2020 /PRNewswire/ -- Recently, Danaher Corporation's Life Sciences platform in China released its mission statement, "Sharing Global Technology to Achieve Health for All," and simultaneously unveiled precision medicine solutions covering three major areas: basic clinical medical research, diagnostics, and personalized treatment. Ms. Zhong Xiaomin, Deputy District Mayor of Changning District, Shanghai; Mr. Fu Daxu, Secretary of the Shanghai Biomedical Science and Technology Industry Promotion Center; Professor Wu Jiarui, Executive Dean of the School of Life Sciences at Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, and Director of the Key Laboratory of Systems Biology at the Chinese Academy of Sciences; along with numerous scholar representatives from leading domestic research institutions, attended the launch event.

Danaher Life Sciences China Region Mission Statement Launch Ceremony

Danaher Life Sciences China Region Mission Statement Launch Ceremony

Actively Respond to "Healthy China 2030"“Outline Plan to Support the Realization of Universal Health”

As China continues to deepen the comprehensive construction of a moderately prosperous society, universal health has become a major issue concerning the guarantee and improvement of people's livelihoods within this framework. The national-level strategic document, the "Outline of the 'Healthy China 2030' Plan," explicitly states that "universal health" is both the strategic theme of Healthy China and the fundamental purpose of building a Healthy China. However, achieving universal health requires further support from innovative technologies and products. The Outline also proposes launching major scientific and technological projects and initiatives, such as those for health security, and strengthening breakthroughs in key technologies including precision medicine.Danaher’s Life Platform has released a development vision and solutions that align precisely with this trend.

Danaher Life Sciences Platform Launches Organically Integrated Precision Medicine Solutions to Fully Meet the Needs of the Chinese MarketTaking basic and clinical medical research as an example, and aligning with customers’ scientific exploration journey from “biological samples” to “data mining and translational outcomes,” we provide a “three-dimensional” precision medicine research solution. This comprehensive approach covers diverse sample types ranging from cells and body fluids to living organisms, and addresses analytical needs across all molecular levels—from genotype to phenotype—through four key steps: fine observation, precise capture, meticulous extraction, and accurate measurement.

Mr. Li Bing, President of Danaher Life Sciences in China, stated, “Danaher Life Sciences’ product technologies and applications have been widely adopted by our customers and partners in China. Meanwhile, we are introducing a series of integrated applications, workflows, and solutions. Furthermore, our platform-based operating model and lean management capabilities will better demonstrate Danaher’s unique value. We believe that these simple, automated, high-throughput solutions and workflows will effectively help customers reduce R&D costs, accelerate R&D processes, and more rapidly translate technological advancements into productive outcomes.”

"Aligning with China's market demands, providing advanced precision medicine solutions"

To achieve more refined and in-depth localization in the Chinese market and better serve Chinese customers and patients, the Danaher Life Sciences Platform China was officially established in June 2019. It encompasses seven companies specializing in various niche sectors, including IDT (Integrated DNA Technologies), Beckman Coulter Life Sciences, Molecular Devices, SCIEX, Agela-Phenomenex, Leica Microsystems, and Pall Corporation. This year, Danaher also acquired GE Healthcare’s Life Sciences business, establishing Cytiva. These companies provide not only innovative technologies and analytical tools for the life sciences field but also integrated scientific solutions encompassing instruments, reagents, software, and technical services.

As one of the most successful industrial merger and acquisition integration companies globally, Danaher is known as the “King of Empowering M&A.” Ms. Wei Chunyan, Vice President of Government Affairs for Danaher China, stated, “Danaher owns more than twenty companies, providing comprehensive products and services to Chinese customers. As Danaher’s most important international market, China has a specially tailored business portfolio that aligns closely with China’s national strategies and development goals. Over the next decade, Danaher will accelerate localization and innovation-driven development based on the needs of the Chinese market, bringing more advanced, faster, and more precise medical diagnostics and life sciences products and technologies to China.”

In October this year, Danaher’s Life Sciences Platform launched its business model in the Shanghai Waigaoqiao Bonded Zone, relocating its logistics center previously based in Hong Kong to the China (Shanghai) Pilot Free Trade Zone. This move accelerates local supply chain capabilities to meet the rapidly evolving market demands in China. Looking ahead, Danaher’s Life Sciences Platform will continue to adapt and strengthen its capacity to serve the Chinese market. By providing leading integrated solutions in biopharmaceuticals and precision medicine, it aims to actively advance the development of China’s life sciences industry while laying a more solid foundation for Danaher’s long-term growth in the country.